Cargando…
A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
The objective of this study was to evaluate the validity and reliability of NG-Test® when used as a finger-prick test on healthcare workers and to compare it to the ELISA Wantai Immunoassay. Fifty-one healthcare workers who were RT-PCR SARS-CoV-2 positive and 59 who were RT-PCR SARS-CoV-2 negative a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717860/ https://www.ncbi.nlm.nih.gov/pubmed/33206004 http://dx.doi.org/10.1080/22221751.2020.1852893 |
_version_ | 1783619388421701632 |
---|---|
author | Garlantézec, Ronan Heslan, Christopher Tadie, Emilie Tattevin, Pierre Thibault, Vincent Paris, Christophe |
author_facet | Garlantézec, Ronan Heslan, Christopher Tadie, Emilie Tattevin, Pierre Thibault, Vincent Paris, Christophe |
author_sort | Garlantézec, Ronan |
collection | PubMed |
description | The objective of this study was to evaluate the validity and reliability of NG-Test® when used as a finger-prick test on healthcare workers and to compare it to the ELISA Wantai Immunoassay. Fifty-one healthcare workers who were RT-PCR SARS-CoV-2 positive and 59 who were RT-PCR SARS-CoV-2 negative accepted to participate in this study. They were subjected to an NG-Test® finger-prick test and collection of a blood sample on the same day. A second NG-Test® on another finger was performed for the first 30 cases and controls and read blinded to the first. Sera obtained from blood samples were used to perform the Wantai SARS-CoV-2 ELISA. The interobserver agreement for the NG-Test® test was perfect (kappa coefficient = 100% [98%–100%]). The sensitivity of NG-Test® was estimated to be 85% [71.9%–92.3%] and the specificity 98.3% [95.0%–100.0%]) for both IgG and IgM. The percentage of agreement between the Wantai immunoassay and NG-Test® was 92.73% for IgG (Kappa = 0.85 [0.75–0.95]) and 65.45% (Kappa = 0.42 [0.26–0.58]) for IgM. Our study highlights the need to validate rapid immunoassay tests under real-life conditions. If NG-Test® is used in seroprevalence surveys, we recommend that its diagnostic performance be taken into consideration to obtain a reliable estimation. |
format | Online Article Text |
id | pubmed-7717860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-77178602020-12-10 A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers Garlantézec, Ronan Heslan, Christopher Tadie, Emilie Tattevin, Pierre Thibault, Vincent Paris, Christophe Emerg Microbes Infect Letter The objective of this study was to evaluate the validity and reliability of NG-Test® when used as a finger-prick test on healthcare workers and to compare it to the ELISA Wantai Immunoassay. Fifty-one healthcare workers who were RT-PCR SARS-CoV-2 positive and 59 who were RT-PCR SARS-CoV-2 negative accepted to participate in this study. They were subjected to an NG-Test® finger-prick test and collection of a blood sample on the same day. A second NG-Test® on another finger was performed for the first 30 cases and controls and read blinded to the first. Sera obtained from blood samples were used to perform the Wantai SARS-CoV-2 ELISA. The interobserver agreement for the NG-Test® test was perfect (kappa coefficient = 100% [98%–100%]). The sensitivity of NG-Test® was estimated to be 85% [71.9%–92.3%] and the specificity 98.3% [95.0%–100.0%]) for both IgG and IgM. The percentage of agreement between the Wantai immunoassay and NG-Test® was 92.73% for IgG (Kappa = 0.85 [0.75–0.95]) and 65.45% (Kappa = 0.42 [0.26–0.58]) for IgM. Our study highlights the need to validate rapid immunoassay tests under real-life conditions. If NG-Test® is used in seroprevalence surveys, we recommend that its diagnostic performance be taken into consideration to obtain a reliable estimation. Taylor & Francis 2020-12-01 /pmc/articles/PMC7717860/ /pubmed/33206004 http://dx.doi.org/10.1080/22221751.2020.1852893 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Letter Garlantézec, Ronan Heslan, Christopher Tadie, Emilie Tattevin, Pierre Thibault, Vincent Paris, Christophe A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers |
title | A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers |
title_full | A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers |
title_fullStr | A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers |
title_full_unstemmed | A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers |
title_short | A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers |
title_sort | lateral flow immunoassay test performance in sars-cov-2 seroprevalence surveys: a validation study among healthcare workers |
topic | Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717860/ https://www.ncbi.nlm.nih.gov/pubmed/33206004 http://dx.doi.org/10.1080/22221751.2020.1852893 |
work_keys_str_mv | AT garlantezecronan alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT heslanchristopher alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT tadieemilie alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT tattevinpierre alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT thibaultvincent alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT parischristophe alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT garlantezecronan lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT heslanchristopher lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT tadieemilie lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT tattevinpierre lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT thibaultvincent lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers AT parischristophe lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers |